

# Rainer Kimmig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7716254/publications.pdf>

Version: 2024-02-01

115  
papers

5,148  
citations

201674

27  
h-index

88630

70  
g-index

125  
all docs

125  
docs citations

125  
times ranked

7034  
citing authors

#	ARTICLE	IF	CITATIONS
1	Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1159-1174.	2.5	6
2	Total mesometrial resection (TMMR) for cervical cancer FIGO IB&#x2014;IIA: first results from the multicentric TMMR register study. <i>Journal of Gynecologic Oncology</i> , 2022, 33, e9.	2.2	7
3	Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray&#x2014;HER2-FISH workflow. <i>Breast Cancer</i> , 2022, 29, 487-497.	2.9	4
4	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	3.7	3
5	Combinatorial Power of cfDNA, CTCs and EVs in Oncology. <i>Diagnostics</i> , 2022, 12, 870.	2.6	18
6	Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes?. <i>Laboratoriums Medizin</i> , 2022, 46, 255-264.	0.6	6
7	In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells. <i>Cancers</i> , 2022, 14, 3299.	3.7	2
8	Zinc distribution within breast cancer tissue of different intrinsic subtypes. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 195-205.	1.7	17
9	Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. <i>Cells</i> , 2021, 10, 212.	4.1	24
10	The role of sentinel-node biopsy in ovarian cancer. <i>Minerva Ginecologica</i> , 2021, 72, 399-403.	0.8	3
11	HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line. <i>Pathology and Oncology Research</i> , 2021, 27, 636088.	1.9	5
12	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 647-655.	2.5	28
13	Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2233-2238.	2.5	20
14	Abnormal expression of the costimulatory molecule B7&#x2014;4 in placental chorionic villous and decidual basalis tissues of patients with preeclampsia and HELLP syndrome. <i>American Journal of Reproductive Immunology</i> , 2021, 86, e13430.	1.2	5
15	Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 85.	8.2	21
16	Targeted breast surgery: Non-direct approach.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12602-e12602.	1.6	0
17	Accuracy of Ultrasonography and Magnetic Resonance Imaging for Preoperative Staging of Cervical Cancer&#x2014;Analysis of Patients from the Prospective Study on Total Mesometrial Resection. <i>Diagnostics</i> , 2021, 11, 1749.	2.6	3
18	Cancer field surgery in endometrial cancer: peritoneal mesometrial resection and targeted compartmental lymphadenectomy for locoregional control. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e7.	2.2	8

#	ARTICLE	IF	CITATIONS
19	Systematic Evaluation of HLA-G 3â€™™Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome. <i>Frontiers in Immunology</i> , 2021, 12, 817132.	4.8	7
20	Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 497-509.	5.4	31
21	Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1658.	2.8	17
22	CCN3 Signaling Is Differently Regulated in Placental Diseases Preeclampsia and Abnormally Invasive Placenta. <i>Frontiers in Endocrinology</i> , 2020, 11, 597549.	3.5	14
23	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	1.4	11
24	Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 1084.	3.7	17
25	Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, tripleâ€™negative breast cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8405-8416.	3.6	13
26	Fetal subdural hematoma, sickle cell disease and storage pool disease: A case report. <i>Case Reports in Women's Health</i> , 2020, 26, e00183.	0.5	0
27	High serum levels of periostin are associated with a poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 515-524.	2.5	15
28	IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 670-683.	2.5	18
29	Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS). <i>Journal of Gynecologic Oncology</i> , 2020, 31, e59.	2.2	97
30	Sentinel-Lymphnode Biopsy in primary breast cancer: 99mTc versus ICGâ€™A prospective, randomized trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 575-575.	1.6	0
31	Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1106.	3.7	30
32	Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 1316-1326.	10.7	39
33	EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4693.	4.1	25
34	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580.	3.2	34
35	HLA-G 3â€™² untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 5407.	3.3	18
36	Human sFLT1 Leads to Severe Changes in Placental Differentiation and Vascularization in a Transgenic hsFLT1/rtTA FGR Mouse Model. <i>Frontiers in Endocrinology</i> , 2019, 10, 165.	3.5	24

#	ARTICLE	IF	CITATIONS
37	Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. <i>BMC Cancer</i> , 2019, 19, 120.	2.6	37
38	Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. <i>Cancers</i> , 2019, 11, 238.	3.7	26
39	Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1072-1076.	2.5	92
40	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1369-1378.	7.0	28
41	What is the evidence for lymphadenectomy in presumed early ovarian cancer?. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1-5.	1.7	1
42	Afamin predicts gestational diabetes in polycystic ovary syndrome patients preconceptionally. <i>Endocrine Connections</i> , 2019, 8, 616-624.	1.9	12
43	Tight interplay in early pregnancy between follistatin and anti-mullerian hormone in women with polycystic ovarian syndrome (PCOS). <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 1307-1316.	1.7	3
44	Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results. <i>Clinical Imaging</i> , 2018, 49, 163-168.	1.5	29
45	Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy. <i>Oncolmmunology</i> , 2018, 7, e1376153.	4.6	86
46	Robotic-Assisted Radical Hysterectomy as Compartmental Resection According to rTMMR and rPMMR. , 2018, , 921-932.		0
47	Robotically Assisted Therapeutic Pelvic and Paraaortic Lymphadenectomy in Uterine Cancer. , 2018, , 933-945.		0
48	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) â€œ Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1089-1109.	1.8	30
49	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) â€œ Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 949-971.	1.8	9
50	Afamin: an early predictor of preeclampsia. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 1009-1016.	1.7	18
51	Minimally invasive surgery for cervical cancer: consequences for treatment after LACC Study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e75.	2.2	49
52	RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 1054-1062.	3.2	55
53	Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 30.	3.3	34
54	Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5550-5550.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Compartmental Theory in Uterine Cancer, Anatomical Considerations and Principles of Compartmental Cervical Cancer Surgery Step by Step. , 2018, , 103-115.		0
56	Peritoneal Mesometrial Resection (PMMR) with Therapeutic Lymphadenectomy (tLNE) in Endometrial Cancer. , 2018, , 117-126.		0
57	Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.. Journal of Clinical Oncology, 2018, 36, 5520-5520.	1.6	1
58	Surgical anatomy of the ligamentous mesometrium and robotically assisted ICG-guided resection in cervical cancer. Gynecologic Oncology Reports, 2017, 20, 4.	0.6	3
59	Technique of ICG-guided Targeted Compartmental Pelvic Lymphadenectomy (TCL) combined with Pelvic Peritoneal Mesometrial Resection (PMMR) for locoregional control of endometrial cancer – A proposal. Gynecologic Oncology Reports, 2017, 20, 125-126.	0.6	13
60	Soluble <sc>CEACAM</sc>1 and <sc>CEACAM</sc>6 are differently expressed in blood serum of pregnant women during normal pregnancy. American Journal of Reproductive Immunology, 2017, 78, e12700.	1.2	7
61	Follistatin during pregnancy and its potential role as an ovarian suppressing agent. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 212, 150-154.	1.1	8
62	Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation. Gynecologic Oncology Reports, 2017, 20, 22-23.	0.6	4
63	Early ovarian cancer surgery with indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, pelvic part). Journal of Gynecologic Oncology, 2017, 28, e68.	2.2	11
64	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	2.5	105
65	Surgical treatment of early ovarian cancer with compartmental resection of regional lymphatic network and indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, paraaortic) Tj ETQq1 1 0.284314 rgBT /Overlo		
66	LION: Lymphadenectomy in ovarian neoplasms – A prospective randomized AGO study group led gynecologic cancer intergroup trial.. Journal of Clinical Oncology, 2017, 35, 5500-5500.	1.6	81
67	ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. Oncotarget, 2017, 8, 24303-24313.	1.8	38
68	EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. Oncotarget, 2017, 8, 48820-48831.	1.8	72
69	Serum concentrations of soluble B7&H4 in early pregnancy are elevated in women with preterm premature rupture of fetal membranes. American Journal of Reproductive Immunology, 2016, 76, 149-154.	1.2	11
70	Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?. Scientific Reports, 2016, 6, 26355.	3.3	25
71	Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system. Gynecologic Oncology Reports, 2016, 16, 24.	0.6	6
72	Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer. Gynecologic Oncology Reports, 2016, 18, 14.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanineâ€green (ICG). <i>Journal of Surgical Oncology</i> , 2016, 113, 554-559.	1.7	31
74	B3-lesions of the breast and cancer risk - an analysis of mammography screening patients. <i>Molecular and Clinical Oncology</i> , 2016, 4, 705-708.	1.0	22
75	Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 153-160.	1.7	19
76	The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients. <i>Human Immunology</i> , 2016, 77, 791-799.	2.4	77
77	Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. <i>Breast Cancer Research</i> , 2016, 18, 20.	5.0	72
78	Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival. <i>Journal of Chemotherapy</i> , 2016, 28, 210-217.	1.5	15
79	Risk-reducing, conservative mastectomy-analysis of surgical outcome and quality of life in 272 implant-based reconstructions using TiLoop(Â®) Bra versus autologous corial flaps. <i>Gland Surgery</i> , 2016, 5, 1-8.	1.1	36
80	The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1139-1148.	2.4	6
81	Changes in the Blood Serum Levels of the Costimulatory Soluble B7â€H4 Molecule in Pregnant Women During the Peripartal Phase. <i>American Journal of Reproductive Immunology</i> , 2015, 74, 209-215.	1.2	12
82	Systematization of Oncoplastic Surgery: Selection of Surgical Techniques and Patient-Reported Outcome in a Cohort of 1,035 Patients. <i>Annals of Surgical Oncology</i> , 2015, 22, 3730-3737.	1.5	36
83	Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 1367-1372.	1.7	1
84	Breast conservative surgery and local recurrence. <i>Breast</i> , 2015, 24, S100-S107.	2.2	23
85	Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 5479-84.	1.1	8
86	The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patients. <i>Oncology Letters</i> , 2014, 7, 2007-2012.	1.8	5
87	Additional B-cell deficiency does not affect growth and angiogenesis of ectopic human endometrium in T-cell-deficient endometriosis mouse models during long-term culture. <i>Journal of Reproductive Immunology</i> , 2014, 106, 50-57.	1.9	3
88	Intraindividual rightâ€left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 181, 124-129.	1.1	5
89	ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance. <i>Clinical Chemistry</i> , 2014, 60, 1282-1289.	3.2	101
90	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.. Journal of Clinical Oncology, 2014, 32, e22032-e22032.	1.6	1
92	The FNTB-609G>C polymorphism as a possible predictive factor for efficacy of lonafarnib-treatment? Exploratory analysis of a randomized phase II clinical trial in stage IIb-IV ovarian cancer, treated with first-line platinum-based chemotherapy with or without lonafarnib.. Journal of Clinical Oncology, 2014, 32, e16534-e16534.	1.6	0
93	Single nucleotide polymorphisms of the EpCAM-coding gene <i>TACSTD1</i> in patients with ovarian cancer and their potential implications in clinical practice.. Journal of Clinical Oncology, 2014, 32, e16515-e16515.	1.6	0
94	Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as â€˜total mesometrial resection (TMMR)â€™™ by M HÄƒckel translated to robotic surgery (rTMMR). World Journal of Surgical Oncology, 2013, 11, 211.	1.9	25
95	Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M HÄƒckel translated to robotic surgery. World Journal of Surgical Oncology, 2013, 11, 198.	1.9	25
96	Definition of Compartment Based Radical Surgery in Uterine Cancerâ€™”Part I: Therapeutic Pelvic and Periaortic Lymphadenectomy by Michael HÄƒckel Translated to Robotic Surgery. ISRN Obstetrics & Gynecology, 2013, 2013, 1-17.	1.2	20
97	Updated results of neoadjuvant chemotherapy with carboplatin AUC 6 and docetaxel 75 mg/m2 in triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2013, 31, 149-149.	1.6	1
98	The haplotype of three polymorphisms in the SATB1 promoter-region and impact on survival in breast cancer patients.. Journal of Clinical Oncology, 2013, 31, 584-584.	1.6	10
99	Clinical relevance of VEGF-receptor status in primary ovarian cancer: A pilot study for future biomarker analyses.. Journal of Clinical Oncology, 2013, 31, 5556-5556.	1.6	0
100	Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).. Journal of Clinical Oncology, 2013, 31, 5575-5575.	1.6	0
101	Evaluation of risk recurrence in early breast cancer assessed by Oncotype DX and tumor cell dissemination to blood and bone marrow.. Journal of Clinical Oncology, 2013, 31, e11516-e11516.	1.6	0
102	Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity. International Journal of Molecular Sciences, 2012, 13, 12000-12016.	4.1	21
103	Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines. BMC Cancer, 2012, 12, 451.	2.6	5
104	Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Research, 2012, 14, R15.	5.0	262
105	Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients.. Journal of Clinical Oncology, 2012, 30, 5042-5042.	1.6	2
106	Risk-reducing surgery by skin-sparing mastectomy (SSM) and immediate implant-based reconstruction with and without titanized meshes and quality of life.. Journal of Clinical Oncology, 2012, 30, 48-48.	1.6	0
107	Triple-negative breast cancer (TNBC) and residual disease (non-pCR): Does size matter?. Journal of Clinical Oncology, 2012, 30, 106-106.	1.6	0
108	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New England Journal of Medicine, 2011, 365, 2484-2496.	27.0	1,843

#	ARTICLE	IF	CITATIONS
109	Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. <i>Anticancer Research</i> , 2011, 31, 3623-8.	1.1	25
110	Catumaxomab in the Treatment of Malignant Ascites: The Evidence of its Therapeutic Value. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S4954.	0.4	0
111	Association of the AA genotype of the BCL2 (â€“938&gt;A) promoter polymorphism with better survival in ovarian cancer. <i>International Journal of Biological Markers</i> , 2009, 24, 223-229.	1.8	10
112	Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R46.	5.0	658
113	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. <i>Breast Cancer Research</i> , 2009, 11, R59.	5.0	217
114	Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. <i>Modern Pathology</i> , 2004, 17, 15-21.	5.5	5
115	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 0, 7, 41677-41690.	1.8	36